Class I recall
This article was originally published in The Gray Sheet
Executive Summary
BioMerieux's VeriCal calibrator set recall has been designated Class I by FDA. The French company initiated the action in August because units are mislabeled and "could result in misdiagnosis or injury to patients, serious illness or death from erroneous calibration data leading to use of improper levels of oral anticoagulant drugs," the firm says. The in vitro diagnostic device, which has been distributed worldwide - including to 437 customers in the U.S. - is used to calibrate prothrombin time and activated partial thromboplastin time for coagulation assays. BioMerieux was involved in another Class I recall in March related to the mislabeling of MDA Simplastin human thromboplastin factor tissue reagents. The firm received warning letters from FDA in July 2004 and July 2005 citing quality system lapses at its Durham, N.C. manufacturing plant (1"The Gray Sheet" Aug. 30, 2004, p. 26)...
You may also be interested in...
bioMerieux Exploring QS Improvements Following IVD Facility Inspections
bioMerieux is bringing in consultants to help resolve quality system issues identified by FDA after an April inspection of the firm's Durham, N.C. facility, the firm reported in a recent earnings release
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.